Amyloid Beta-42

Gene

Related News

Anti-Epileptic Drug Levetiracetam Prevents Alzheimer's Amyloid-Beta Formation in Preclinical Study

Jul 15, 2026

A preclinical study shows that the anti-epileptic drug levetiracetam can prevent the formation of amyloid-beta 42 in neurons by modulating synaptic vesicle recycling. Analysis of patient records indicates a modest delay in cognitive decline among Alzheimer's patients taking the drug, suggesting potential for very early preventive use.

Experts prioritize Zostavax, sildenafil and riluzole for Alzheimer disease trials

Apr 10, 2026

A Delphi consensus of 23 experts identified Zostavax, sildenafil and riluzole as high-priority candidates for Alzheimer disease clinical trials. Caregivers ranked the herpes zoster vaccine highest for acceptability and perceived benefit–risk balance.

Anti-Seizure Drug Levetiracetam Shows Promise in Preventing Alzheimer's Disease

Mar 20, 2026

Northwestern University researchers found that levetiracetam, an FDA-approved anti-seizure medication, prevents formation of toxic amyloid-beta 42 peptides in the brain, offering a potential strategy for early Alzheimer's prevention.